Clinical trials: Pulse Wave Velocity
Hypertension
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated…
- Trial name
- NCT01692301
- Testing
- LCZ696, Olmesartan, amlodipine
- Where
- 47 sites in United States, Argentina and 10 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Hypertension
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
- Trial name
- NCT02336607
- Testing
- Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.
- Trial name
- NCT00857766
- Testing
- ADVAIR DISKUS™ 250/50mcg
- Where
- 24 sites in United States
- Volunteers
- 249 people
- Sponsor
- GlaxoSmithKline